Key result
Women with AFib on VKAs show ~1.4% lower TTR than men.
Why the study?
Sex disparities in INR control and patterns of switching to NOACs among AF patients receiving VKA have been scarcely studied in real-world settings.
Are there sex disparities in the quality of INR control and switching to NOACs among atrial fibrillation patients treated with VKAs?
Cross-Sectional (n=22,629)
Yes
Are there sex disparities in the quality of INR control and switching to NOACs among atrial fibrillation patients treated with VKAs?
Absolute Event Rate: 62.3% vs 63.7%
p-value: p=<0.001
INR control in AF patients on VKAs is suboptimal, particularly in women, and rates of switching to NOACs in poorly controlled patients remain low, suggesting clinical inertia.
May warrant closer INR monitoring in women on VKAs; leaves open whether targeted NOAC switching narrows sex disparities.
BACKGROUND: Worldwide, there is growing evidence that quality of international normalized ratio (INR) control in atrial fibrillation patients treated with Vitamin K Antagonists (VKA) is suboptimal. However, sex disparities in population-based real-world settings have been scarcely studied, as well as patterns of switching to second-line Non-VKA oral anticoagulants (NOAC). We aimed to assess the quality of INR control in atrial fibrillation patients treated with VKA in the region of Valencia, Spain, for the whole population and differencing by sex, and to identify factors associated with poor control. We also quantified switching to Non-VKA oral anticoagulants (NOAC) and we identified factors associated to switching. METHODS: This is a cross-sectional, population-based study. Information was obtained through linking different regional electronic databases. Outcome measures were Time in Therapeutic Range (TTR) and percentage of INR determinations in range (PINRR) in 2015, and percentage of switching to NOAC in 2016, for the whole population and stratified by sex. RESULTS: We included 22,629 patients, 50.4% were women. Mean TTR was 62.3% for women and 63.7% for men, and PINNR was 58.3% for women and 60.1% for men (p<0.001). Considering the TTR<65% threshold, 53% of women and 49.3% of men had poor anticoagulation control (p<0.001). Women, long-term users antiplatelet users, and patients with comorbidities, visits to Emergency Department and use of alcohol were more likely to present poor INR control. 5.4% of poorly controlled patients during 2015 switched to a NOAC throughout 2016, with no sex differences. CONCLUSION: The quality of INR control of all AF patients treated with VKA in 2015 in our Southern European region was suboptimal, and women were at a higher risk of poor INR control. This reflects sex disparities in care, and programs for improving the quality of oral anticoagulation should incorporate the gender perspective. Clinical inertia may be lying behind the observed low rates of switching in patient with poor INR control.
No takes yet. Share an insight, caveat, or question.
García‐Sempere et al. (2019) conducted a cross-sectional in Atrial fibrillation (n=22,629). Acenocoumarol (Female patients) vs. Acenocoumarol (Male patients) was evaluated on Mean Time in Therapeutic Range (TTR) (p=<0.001). Women with atrial fibrillation treated with Vitamin K antagonists had significantly lower mean Time in Therapeutic Range compared to men (62.3% vs 63.7%, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: